The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics
- 3 November 2015
- journal article
- review article
- Published by Elsevier BV in Drug Discovery Today
- Vol. 20 (12), 1439-1450
- https://doi.org/10.1016/j.drudis.2015.10.017
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Current Methodological Issues in the Economic Assessment of Personalized MedicineValue in Health, 2013
- Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest GroupValue in Health, 2012
- Which health technologies should be funded? A prioritization framework based explicitly on value for moneyIsrael Journal of Health Policy Research, 2012
- Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United StatesJournal of Medical Economics, 2011
- Quantifying factors for the success of stratified medicineNature Reviews Drug Discovery, 2011
- Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patientsCancer, 2009
- A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker CodevelopmentJNCI Journal of the National Cancer Institute, 2009
- The JUPITER TrialCirculation: Cardiovascular Quality and Outcomes, 2009
- Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnosticsExpert Opinion on Medical Diagnostics, 2008
- Diagnostics and biomarker development: priming the pipelineNature Reviews Drug Discovery, 2006